CFDE Workbench
DataKnowledgeCloudtrainingcoordination
CFDE Workbench

garenoxacin (f0179598-bb1e-481b-812a-d8c880c63679) (Collection)

Project:

Drugmonizome

Project (Entity type)
Dcc Asset:

IDG C2M2 2024-01-09 datapackage validated.zip

Processed File (Entity type)
Dcc:

IDG

DCC (Entity type)
Compound:

Garenoxacin

Compound (Entity type)
Collection:

f0179598-bb1e-481b-812a-d8c880c63679.json

File (Entity type)
Persistent Id:f0179598-bb1e-481b-812a-d8c880c63679.json
Description:Metadatata for garenoxacin
Creation Time:2021-09-08T00:00:00
Results found

Linked to

 

Label

Description

 

Compound

Garenoxacin

Compound (Entity type)

nan

File

f0179598-bb1e-481b-812a-d8c880c63679.json

File (Entity type)

A file from IDG as part of the Drugmonizome project

  • Compound

    Garenoxacin

    Compound (Entity type)

    nan

  • File

    f0179598-bb1e-481b-812a-d8c880c63679.json

    File (Entity type)

    A file from IDG as part of the Drugmonizome project

    • DISPLAY PER PAGE
    CFDE Workbench
    Report a bug
    Consortium
    About the CFDECF ProgramsCFDE CentersPartnershipsPilot Projects
    Community
    Workbench TutorialTraining & OutreachDocumentationGet QR CodesFunding Opportunities
    Resources
    Data & MetadataToolsChatbotUse CasesPublications
    @CFDE Workbench 2026
    The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.
    Consortium
    About the CFDECF ProgramsCFDE CentersPartnershipsPilot Projects
    Community
    Workbench TutorialTraining & OutreachDocumentationGet QR CodesFunding Opportunities
    Resources
    Data & MetadataToolsChatbotUse CasesPublications
    CFDE Workbench
    Report a bug
    The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.
    @CFDE Workbench 2026
    This repository is under review for potential modification in compliance with Administration directives.